SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001127602-19-035549
Filing Date
2019-12-19
Accepted
2019-12-19 17:49:56
Documents
1
Period of Report
2019-12-17

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT form4.html 4  
1 PRIMARY DOCUMENT form4.xml 4 3731
  Complete submission text file 0001127602-19-035549.txt   5125
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Issuer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703
Business Address
Sniecinski Megan (Reporting) CIK: 0001781480 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-23186 | Film No.: 191297223